临床试验 以下为当前的临床试验。534 研究 肿瘤科(内科) (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 A Study to Evaluate DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study Rochester, Minn. The purpose of this study is train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features. Screening for High Frequency Malignant Disease Rochester, Minn., La Crosse, Wis., Eau Claire, Wis. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations. Cancer Distress Management Program for Liver and Biliary Cancer within a SPORE Rochester, Minn. The aim of this study is to develop a feasible, acceptable, and sustainable comprehensive cancer distress management program that is tailored to the unique needs of cancer patient survivors. A Study Evaluating the Safety and Effectiveness of Therapies in Patients with Metastatic Colorectal Cancer Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study for the Inavo + Cetux Arm (A): To evaluate the effectiveness of Inavo + Cetux in PIK3CA-mutated colorectal cancer (CRC) with no detected RAS (KRAS, NRAS) or BRAFV600E mutations. The purpose of this study for the Inavo + Bev Arm (B_: To evaluate the effectiveness Inavo + Bev in PIK3CA-mutated, RAS (KRAS, NRAS)-mutated CRC. The purpose of this study for the Atezo+SY-5069 Arm (C): To evaluate the effectiveness of atezolizumab and SY-5609 treatment combination on patients with mCRC. The purpose of this study for the GDC-6036+cetuzimab+FOLFOX Arm (E): To evaluate the effectivenss of GDC-6036 plus cetuximab plus FOLFOX on patients with mCRC. The purpose of this study for the GDC-6036 plus cetuximab Arm (F): To evaluate the effectivenss of GDC-6036 plus cetuximab on patients with mCRC. The purpose of this study for the atezolizumab plus tiragolumab or atezolizumab plus tiragolumab and bevacizumab Arm (MSI-H): To evaluate the effectivenss of atezolizumab plus tiragolumab or atezolizumab plus tiragolumab and bevacizumab. A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM Jacksonville, Fla. The purpose of this study is to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent glioblastoma (GBM). Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors Rochester, Minn. The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors. The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood. ROF2181 Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. Currently, only a few international institutions use CIRT to treat pelvic bone sarcomas. Accordingly, data evaluating the potential differences in oncological outcomes, toxicities, and functional outcomes between CIRT and the more readily accessible local therapies of surgery and PT is scarce. For this reason, we propose conducting a prospective comparative effectiveness study evaluating functional outcomes, toxicities, and local control in patients with pelvic bone sarcomas treated with surgery, PT, and CIRT. TheraSphere With and Without Durvalumab and Tremelimumab for HCC Jacksonville, Fla. The objective of the ROWAN clinical study is to assess the the durability of local tumor control in Hepatocellular Carcinoma (HCC) patients who receive TheraSphere followed by durvalumab and tremelimumab, compared to those who receive TheraSphere treatment alone. Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the effectiveness of the triple combination therapy, DTRM-555, in patients with R/R CLL or R/R non-Hodgkin's lymphoma. Mayo Clinic Vestibular Schwannoma Quality of Life Index Assessment Rochester, Minn. The purpose of the study is to conduct cognitive testing of the recently published Mayo Clinic Vestibular Schwannoma Quality of Life (VSQOL) Index. Pagination 临床研究 PrevPrevious Page Go to page 5050 Go to page 5151 Go to page 5252 Go to page 5353 Go to page 5454 NextNext Page 申请预约 专长与排名研究 May 09, 2023 在《美国新闻与世界报道》2023-2024 年度全美最佳癌症医院评选中,妙佑医疗国际明尼苏达州罗切斯特院区、妙佑医疗国际佛罗里达州杰克逊维尔院区和妙佑医疗国际亚利桑那州凤凰城/斯科茨代尔院区均名列前茅。 了解更多关于这一最高荣誉的信息 肿瘤科(内科)科室首页部分概述主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 研究完全以患者为中心。 请参见副本 供视频使用 研究完全以患者为中心。 [音乐播放] 妙佑医疗国际神经学教授 Joseph Sirven 医学博士:妙佑医疗的使命以患者为中心。患者第一。我们的使命和研究是为了更好地帮助患者,提供以患者为中心的护理。在很多方面,这是一个循环。这个过程可能很简单,就是先在实验室里出现一个想法,然后带到病床旁加以实施,如果一切顺利,对患者有所助益, 就形成标准。我认为这就是妙佑医疗国际研究方法的一个独特之处,而这种以患者为中心的方式,也是妙佑医疗在众多医疗机构中脱颖而出的原因之一。 部分预约门诊概述主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 ORG-20180179 医学科室与中心 肿瘤科(内科)